跳至主要内容
临床试验/EUCTR2020-001992-34-DE
EUCTR2020-001992-34-DE进行中(未招募)1 期

Clinical Trial Exit Interview Study in Cutaneous T-cell Lymphoma (CTCL) to Capture Meaningful Treatment Benefit from a Patient’s Perspective

GALDERMA Research & Development LLC0 个研究点目标入组 30 人开始时间: 2020年8月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Had participated or is currently participating in Galderma’s Phase 2 clinical trial of the CD11301 gel and has completed cycle 2 (week 24)
  • or Patient has exited the study trial early due to patient request or clinician judgement
  • 2. Able to remember experience with taking clinical trial treatment
  • 3.Willing and able to participate in a 60-90 minute telephone interview
  • 4.Able to understand, read, and speak native English (US) or German (Germany) sufficiently to participate in the interview
  • 5. Willing and able to provide oral and written informed consent
  • 6. Willing and consenting to be audio-recorded during the discussion.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • 1. Hearing difficulty, visual impairment, acute psychopathology, or insufficient knowledge of English (US) or German (Germany) that, in the opinion of the investigator/interviewer, could interfere with patient ability to provide oral consent and written consent and complete an interview.
  • 2. Not able to remember experience with taking clinical trial treatment in the opinion of the investigator.

研究者

相似试验